Insulasta

Insulasta is a brand name for the drug exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is used to manage type 2 diabetes by helping to control blood sugar levels. Insulasta works by mimicking the action of a natural hormone in the body, which helps to regulate blood sugar and insulin levels.

The drug is available in two forms: Insulasta and Insulasta Lenti. Insulasta is administered once daily, while Insulasta Lenti is administered once weekly. Both forms are administered via subcutaneous injection.

Insulasta is typically prescribed for adults with type 2 diabetes who are unable to achieve adequate glycemic control with diet and exercise alone. It is also used in combination with other diabetes medications, such as metformin or sulfonylureas.

Common side effects of Insulasta include nausea, vomiting, diarrhea, constipation, and injection site reactions. Serious side effects are rare but can include pancreatitis, which is a potentially life-threatening inflammation of the pancreas.

Insulasta is not recommended for use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). It is also not recommended for use in patients with severe kidney impairment.

Insulasta is a prescription medication and should only be used under the guidance of a healthcare professional. It is important to follow the prescribed dosage and administration instructions to ensure safe and effective use.